Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Temozolomide and thalidomide combination effective against malignant melanoma spread to the central nervous system

22.08.2008
Researchers at the Odense University Hospital, Denmark, have found that combining thalidomide with temozolomide may double its effectiveness, over temozolomide alone, for malignant melanoma with brain metastases.

The non-randomised phase II trial, published in the online journal ecancermedicalscience, investigated the combination of thalidomide and temozolomide. It is the first phase II study combining a new cyclic regimen of temozolomide (150mg /m2 daily, 7 days on 7days off) and thalidomide, for patients with malignant melanoma suffering from brain metastases, to show a meaningful response rate.

Melanoma is the third most common cause of metastases in the central nervous system. Thalidomide is known to prevent new blood vessels growing from pre-existing vessels and thus inhibit tumour growth, and is also known to adjust the body’s immune response. Temozolomide is a chemotherapy alkylating agent commonly used for primary brain tumours, but also active in melanoma.

The researchers observed a response rate of 17.5% for temozolomide and thalidomide combined, around twice the response rate of the standard schedule of temozolomide alone (6-9% established in a previous study).

A statistically significant correlation was found between efficacy and lymphopenia (lowered white blood cell count).

Lead author Dr Lene Vestermark concluded: “The combination of temozolomide using the dose-intense schedule and thalidomide at 100-200 mg/day is a safe regimen leading to clinical efficacy in patients with brain metastases from malignant melanoma.

Most importantly it seems that patients who develop lymphopenia during therapy have a higher chance of obtaining objective response. The potential immunologic mechanism behind this will be the subject of future investigations, focusing on the potential benefit of regulatory T Cell down-regulation. The correlation between lymphopenia and objective response needs further investigation.”

Further evaluations using larger patient numbers and including different therapy schedules will be considered for the future.

Linda Cairns | alfa
Further information:
http://www.ecancermedicalscience.com

More articles from Health and Medicine:

nachricht Finnish research group discovers a new immune system regulator
23.02.2018 | University of Turku

nachricht Minimising risks of transplants
22.02.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Attoseconds break into atomic interior

A newly developed laser technology has enabled physicists in the Laboratory for Attosecond Physics (jointly run by LMU Munich and the Max Planck Institute of Quantum Optics) to generate attosecond bursts of high-energy photons of unprecedented intensity. This has made it possible to observe the interaction of multiple photons in a single such pulse with electrons in the inner orbital shell of an atom.

In order to observe the ultrafast electron motion in the inner shells of atoms with short light pulses, the pulses must not only be ultrashort, but very...

Im Focus: Good vibrations feel the force

A group of researchers led by Andrea Cavalleri at the Max Planck Institute for Structure and Dynamics of Matter (MPSD) in Hamburg has demonstrated a new method enabling precise measurements of the interatomic forces that hold crystalline solids together. The paper Probing the Interatomic Potential of Solids by Strong-Field Nonlinear Phononics, published online in Nature, explains how a terahertz-frequency laser pulse can drive very large deformations of the crystal.

By measuring the highly unusual atomic trajectories under extreme electromagnetic transients, the MPSD group could reconstruct how rigid the atomic bonds are...

Im Focus: Developing reliable quantum computers

International research team makes important step on the path to solving certification problems

Quantum computers may one day solve algorithmic problems which even the biggest supercomputers today can’t manage. But how do you test a quantum computer to...

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Basque researchers turn light upside down

23.02.2018 | Physics and Astronomy

Finnish research group discovers a new immune system regulator

23.02.2018 | Health and Medicine

Attoseconds break into atomic interior

23.02.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>